BioVie Inc. (BIVI)
NASDAQ: BIVI · Real-Time Price · USD
0.8000
-0.1098 (-12.07%)
At close: Nov 20, 2026, 4:00 PM EST
0.9393
+0.1393 (17.41%)
After-hours: Nov 20, 2026, 7:35 PM EST
BioVie Employees
BioVie had 13 employees as of June 30, 2026. The number of employees did not change compared to the previous year. That makes BioVie the 39,542nd largest employer in the world and 5,810th in the United States.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,737,721
Market Cap
8.58M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 13 | 0 | - | 13 | 0 |
| Jun 30, 2025 | 13 | -1 | -7.14% | 13 | 0 |
| Jun 30, 2024 | 14 | -4 | -22.22% | 14 | 0 |
| Jun 30, 2023 | 18 | 5 | 38.46% | 18 | 0 |
| Jun 30, 2022 | 13 | 7 | 116.67% | 13 | 0 |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 138 |
| aTyr Pharma | 60 |
| CytoMed Therapeutics | 42 |
| Palatin Technologies | 25 |
| BioLineRx | 24 |
| Bolt Biotherapeutics | 23 |
| Psyence Biomedical | 12 |
| Purple Biotech | 10 |
BIVI News
- 4 days ago - BioVie Presents New Biomarker Data Highlighting Biomarker-Defined Endotypes and Neuropeptide Y Response to Bezisterim at the 4th Long COVID International Conference 2026 - GlobeNewsWire
- 10 days ago - BioVie Transcript: AGM 2026 - Transcripts
- 10 days ago - BioVie Invited to Present Data on Bezisterim in Parkinson's Disease at the AD/PD2027 International Conference on Alzheimer's & Parkinson's Diseases - GlobeNewsWire
- 10 days ago - BioVie Slides: Corporate presentation - Filings
- 11 days ago - BioVie presents new biomarker data from ADDRESS-LC trial of bezisterim - TheFly
- 11 days ago - BioVie Presents New Biomarker Data from the ADDRESS-LC Trial of Bezisterim in Long COVID at the NIH RECOVER-TLC Third Annual Workshop - GlobeNewsWire
- 14 days ago - BioVie Quarterly report: Q1 2027 - Filings
- 16 days ago - BioVie prices 2.96M shares at $1.60 in registered direct offering - TheFly